Journal of Pharmaceutical Research

The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader).

If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.

Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link above.

Fullscreen Fullscreen Off


The drugs currently available for treatment of glaucoma are α-blockers, sympathomimetics, carbonic anhydrase inhibitors (CAIs) and prostaglandin analogues1. Apart from their use in glaucoma to reduce IOP, the antiglaucoma drugs are also used routinely for pre-operative reduction of IOP even in nonglaucomatous patients subjected for intraocular surgery to prevent expulsive haemorrhage and bulging of anterior segment.

Objectives: To assess the safety and tolerability of 2% dorzolamide and 0.5% timolol maleate in Pre-operative Cataract patients.

Materials and Methods: A prospective, comparative study enrolling 60 Pre-operative Cataract patients (30 in each group) attending Ophthalmology inpatient department in Kempe Gowda Institute of Medical Science Hospital and Research Centre. Dorzolamide was instilled thrice daily and timolol maleate twice daily for 2 days. IOP was measured on zero, 2nd, 24th and 48th hours and also looked for side effects.

Results: The mean reduction of IOP was 17.1% with dorzolamide and 18.9% with timolol maleate. Both the drugs were tolerated very well without any systemic adverse effect and the local side effects were comparatively less with dorzolamide.

Conclusion: Efficacy of dorzolamide in decreasing IOP in Pre-operative Cataract patients was almost comparable to timolol, and dorzolamide appeared to be relatively better tolerated.


Keywords

Pre-Operative, Cataract, IOP, Dorzolamide, Timolol Maleate.
User
Notifications
Font Size